Search results
The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued updated interim recommendations for the use of the Moderna COVID-19 (mRNA-1273) vaccine against COVID-19. This article provides a summary of those interim recommendations; you may access the full guidance document here. Here is what you need to know.
Before COVID-19 vaccines such as Moderna and Pfizer/BioNTech were authorized for use in the general population, they had to pass phase III studies involving tens of thousands of people. Any serious side effects that did not appear during that testing are likely to occur less often than ~1 in 10,000 cases.
Retrieved 3 October 2022. Die STIKO empfiehlt für die COVID-19-Grundimmunisierung bei unter 30-Jährigen nur noch den mRNA-Impfstoff Comirnaty von BioNTech/Pfizer, da in dieser Altersgruppe das Risiko einer Myokarditis nach Impfung mit dem mRNA-Impfstoff Spikevax von Moderna höher ist als mit Comirnaty.
4 COVID-19 Vaccine Moderna safety update. 5 Not a Controversy. 3 comments. 6 Controversy section. 3 comments. 7 Date format. 1 comment. 8 ...
e. Sputnik V ( Russian: Спутник V, the brand name from the Russian Direct Investment Fund or RDIF) or Gam-COVID-Vac ( Russian: Гам-КОВИД-Вак, the name under which it is legally registered and produced [3]) is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and ...
Dec 22, 2020 · After releasing positive interim results from its phase 3 trial on Nov. 16, 2020, Moderna announced on Nov. 30 that its vaccine had an efficacy of 94.1% in preventing disease in adults. The ...
2022. Jan The U.S. and COVAX provided 7 million Pfizer COVID-19 vaccine doses to Bangladesh. January 20, the U.S., in partnership with COVAX, delivered an additional 337,350 doses of the Johnson & Johnson COVID-19 vaccine to Bangladesh. The U.S. donated 10 million additional Pfizer COVID-19 vaccine doses to Bangladesh via COVAX, on February 1.
